+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Tumor Ablation Market, by Treatment, by Technology, by Application, by Region, Industry Analysis and Forecast, 2019 - 2025

  • ID: 5006206
  • Report
  • February 2020
  • Region: Global
  • 233 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • AngioDynamics, Inc.
  • EDAP TMS S.A.
  • Medtronic PLC
  • Mermaid Medical A/S
  • Misonix, Inc.
  • SonaCare Medical, LLC
The Global Tumor Ablation Market size is expected to reach $1.7 billion by 2025, rising at a market growth of 10.9% CAGR during the forecast period. Tumor ablation is a minimally invasive image-guided procedure that is used to treat liver, kidney, soft tissue, and bone tumors. By using heat, chemicals, and low temperature, this procedure ensures high efficacy of tumor treatment eliminating most of the possible side effects. Tumor ablation is a procedure that has achieved greater effectiveness in the treatment of tumor cells with limited toxicity or side effects. The destruction of tumors is done using heat, low temperature, and chemical agents, which are inserted through a small hole in the tumor regions with a guided needle.

The ongoing technological advancements have made tumor ablation treatment a safe and painless one especially due to impressive results during and after the procedure. With increasing awareness in the healthcare industry around the world, cancer ablation is becoming increasingly popular for different types of cancer as one of the most favored cancer therapy methods. Hospitals and healthcare centers are recognizing the immense potential of cancer ablation therapy, thereby supporting their patients with the facility that is expected to further assist in facilitating the therapeutic.

As the trend towards decreased invasiveness of medical procedures persists, image-guided percutaneous ablation has started supplanting surgery for local control of small tumors in the liver, kidney, and lung. New ablation techniques and refinement of existing technologies will make it possible to treat larger and more complex tumors in these and other organs. At the same time, advances in intra-procedural imaging aim to boost treatment quality and complications. Advancements in intraprocedural imaging have enhanced treatment preparation and provided a more accurate assessment of the ablation zone during treatment. As these techniques mature, the reason for percutaneous ablation continues to expand and ablation appears to be gradually supplanting for local tumor therapy.

Based on Treatment, the market is segmented into Surgical Ablation, Laparoscopic Ablation and Percutaneous Ablation. Based on Technology, the market is segmented into Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation and Other Technology. Based on Application, the market is segmented into Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Cancer. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix, Medtronic PLC and Johnson and Johnson (Ethicon, Inc.) are some of the forerunners in the Tumor Ablation Market. Companies such as Boston Scientific Corporation, AngioDynamics, Inc., HealthTronics, Inc., Misonix, Inc., and EDAP TMS S.A. are some of the key innovators in Tumor Ablation Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Johnson and Johnson (Ethicon, Inc.), Boston Scientific Corporation, Misonix, Inc., EDAP TMS S.A., Theraclion SA, AngioDynamics, Inc., Mermaid Medical A/S, HealthTronics, Inc. (Altaris Capital Partners, LLC), and SonaCare Medical, LLC.

Strategies deployed in Tumor Ablation Market

Partnerships, Collaborations, and Agreements:

Dec-2019: Misonix signed distribution agreement with CryoLife, a leading vascular and cardiac surgery company. The agreement provides Misonix with the US exclusive commercialization rights for CryoLife's NeoPatch product for the treatment of a broad range of indications outside vascular and cardiac surgery.

Oct-2017: EDAP TMS signed an agreement with Theraclion, a French HIFU company. Under the agreement, the former company distributes Echopulse system in France with the help of the latter company. Echopulse uses EDAP's proprietary HIFU technology for addressing the breast fibroadenomas and benign thyroid nodules.

Product Launches:

Aug-2018: J&J released NEUWAVE, a microwave ablation system. This is the first minimally invasive device that puts electrodes into cancer cells and increases the temperature around them for burning off the cancer cells.

Apr-2017: Medtronic Canada, a subsidiary of Medtronic PLC launched OsteoCool RF Ablation System in Canada. This is the only cooled radiofrequency (RF) ablation technology, which provides simultaneous and dual-probe capabilities. This provides a minimally-invasive option for the treatment of painful bone metastases.

Acquisition and Mergers:

Oct-2019: AngioDynamics announced the acquisition of Eximo Medical, Ltd., a medical device company. The Vascular Interventions and Therapies (VIT) product portfolio of AngioDynamics has been expanded through the addition of proprietary laser technology.

Jun-2019: Boston Scientific completed the acquisition of Vertiflex, Inc., a producer of spinal spacer implants. The acquisition expanded its portfolio of interventional pain therapies.

Apr-2019: J&J completed the acquisition of Auris Health, Inc., a surgical robotics company. The acquisition provided a lung cancer diagnostic and treatment tool to the former company. Through this acquisition, the company has been able to expand its health portfolio.
Jan-2019: Medtronic announced an agreement to acquire Epix Therapeutics, a company engaged in the manufacturing of catheter-based system for the treatment of patients with AFIB. The acquisition is expected to expand the company's cardiac ablation portfolio.

Sep-2018: AngioDynamics acquired RadiaDyne, a medical diagnostic and device company. The company has expanded its oncology business through the addition of RadiaDyne’s early-stage, proprietary OARtrac real-time radiation dose monitoring platform, and other market-leading oncology solutions.

Jul-2018: Boston Scientific signed an agreement to acquire Cryterion Medical. The acquisition is expected to enable the former company in providing cryothermal as well as radiofrequency (RF) single-shot, balloon-based ablation therapies.

Mar-2018: Boston Scientific acquired EMcision Ltd., a company engaged in developing and commercializing proprietary medical devices. The acquisition helped the company in improving the quality of life of cancer patients on a much larger scale.

Scope of the Study

Market Segmentation:

By Treatment
  • Surgical Ablation
  • Laparoscopic Ablation and
  • Percutaneous Ablation
By Technology
  • Radiofrequency Ablation
  • Microwave Ablation
  • Cryoablation
  • Irreversible Electroporation and
  • Other Technology
By Application
  • Liver Cancer
  • Breast Cancer
  • Lung Cancer
  • Kidney Cancer
  • Prostate Cancer and
  • Other Cancer
By Geography

North America
  • US
  • Canada
  • Mexico
  • Rest of North America
Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Australia
  • Rest of Asia Pacific
LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Medtronic PLC
  • Johnson and Johnson (Ethicon, Inc.)
  • Boston Scientific Corporation
  • Misonix, Inc.
  • EDAP TMS S.A.
  • Theraclion SA
  • AngioDynamics, Inc.
  • Mermaid Medical A/S
  • HealthTronics, Inc. (Altaris Capital Partners, LLC)
  • SonaCare Medical, LLC
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AngioDynamics, Inc.
  • EDAP TMS S.A.
  • Medtronic PLC
  • Mermaid Medical A/S
  • Misonix, Inc.
  • SonaCare Medical, LLC
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Tumor Ablation Market, by Treatment
1.4.2 Global Tumor Ablation Market, by Technology
1.4.3 Global Tumor Ablation Market, by Application
1.4.4 Global Tumor Ablation Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Mergers & Acquisitions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2015-2019)
3.3.2 Key Strategic Move: (Acquisition and Mergers : 2019-Oct - 2016-Jan) Leading Players

Chapter 4. Global Tumor Ablation Market by Treatment
4.1 Global Surgical Ablation Market by Region
4.2 Global Laparoscopic Ablation Market by Region
4.3 Global Percutaneous Ablation Market by Region

Chapter 5. Global Tumor Ablation Market by Technology
5.1 Global Radiofrequency Ablation Market by Region
5.2 Global Microwave Ablation Market by Region
5.3 Global Cryoablation Market by Region
5.4 Global Irreversible Electroporation Market by Region
5.5 Global Other Technology Market by Region

Chapter 6. Global Tumor Ablation Market by Application
6.1 Global Liver Cancer Market by Region
6.2 Global Breast Cancer Market by Region
6.3 Global Lung Cancer Market by Region
6.4 Global Kidney Cancer Market by Region
6.5 Global Prostate Cancer Market by Region
6.6 Global Other Cancer Market by Region

Chapter 7. Global Tumor Ablation Market by Region
7.1 North America Tumor Ablation Market
7.1.1 North America Tumor Ablation Market by Treatment
7.1.1.1 North America Surgical Ablation Market by Country
7.1.1.2 North America Laparoscopic Ablation Market by Country
7.1.1.3 North America Percutaneous Ablation Market by Country
7.1.2 North America Tumor Ablation Market by Technology
7.1.2.1 North America Radiofrequency Ablation Market by Country
7.1.2.2 North America Microwave Ablation Market by Country
7.1.2.3 North America Cryoablation Market by Country
7.1.2.4 North America Irreversible Electroporation Market by Country
7.1.2.5 North America Other Technology Market by Country
7.1.3 North America Tumor Ablation Market by Application
7.1.3.1 North America Liver Cancer Market by Country
7.1.3.2 North America Breast Cancer Market by Country
7.1.3.3 North America Lung Cancer Market by Country
7.1.3.4 North America Kidney Cancer Market by Country
7.1.3.5 North America Prostate Cancer Market by Country
7.1.3.6 North America Others Tumor Ablation Market by Country
7.1.4 North America Tumor Ablation Market by Country
7.1.4.1 US Tumor Ablation Market
7.1.4.1.1 US Tumor Ablation Market by Treatment
7.1.4.1.2 US Tumor Ablation Market by Technology
7.1.4.1.3 US Tumor Ablation Market by Application
7.1.4.2 Canada Tumor Ablation Market
7.1.4.2.1 Canada Tumor Ablation Market by Treatment
7.1.4.2.2 Canada Tumor Ablation Market by Technology
7.1.4.2.3 Canada Tumor Ablation Market by Application
7.1.4.3 Mexico Tumor Ablation Market
7.1.4.3.1 Mexico Tumor Ablation Market by Treatment
7.1.4.3.2 Mexico Tumor Ablation Market by Technology
7.1.4.3.3 Mexico Tumor Ablation Market by Application
7.1.4.4 Rest of North America Tumor Ablation Market
7.1.4.4.1 Rest of North America Tumor Ablation Market by Treatment
7.1.4.4.2 Rest of North America Tumor Ablation Market by Technology
7.1.4.4.3 Rest of North America Tumor Ablation Market by Application
7.2 Europe Tumor Ablation Market
7.2.1 Europe Tumor Ablation Market by Treatment
7.2.1.1 Europe Surgical Ablation Market by Country
7.2.1.2 Europe Laparoscopic Ablation Market by Country
7.2.1.3 Europe Percutaneous Ablation Market by Country
7.2.2 Europe Tumor Ablation Market by Technology
7.2.2.1 Europe Radiofrequency Ablation Market by Country
7.2.2.2 Europe Microwave Ablation Market by Country
7.2.2.3 Europe Cryoablation Market by Country
7.2.2.4 Europe Irreversible Electroporation Market by Country
7.2.2.5 Europe Other Technology Market by Country
7.2.3 Europe Tumor Ablation Market by Application
7.2.3.1 Europe Liver Cancer Market by Country
7.2.3.2 Europe Breast Cancer Market by Country
7.2.3.3 Europe Lung Cancer Market by Country
7.2.3.4 Europe Kidney Cancer Market by Country
7.2.3.5 Europe Prostate Cancer Market by Country
7.2.3.6 Europe Others Cancer Market by Country
7.2.4 Europe Tumor Ablation Market by Country
7.2.4.1 Germany Tumor Ablation Market
7.2.4.1.1 Germany Tumor Ablation Market by Treatment
7.2.4.1.2 Germany Tumor Ablation Market by Technology
7.2.4.1.3 Germany Tumor Ablation Market by Application
7.2.4.2 UK Tumor Ablation Market
7.2.4.2.1 UK Tumor Ablation Market by Treatment
7.2.4.2.2 UK Tumor Ablation Market by Technology
7.2.4.2.3 UK Tumor Ablation Market by Application
7.2.4.3 France Tumor Ablation Market
7.2.4.3.1 France Tumor Ablation Market by Treatment
7.2.4.3.2 France Tumor Ablation Market by Technology
7.2.4.3.3 France Tumor Ablation Market by Application
7.2.4.4 Russia Tumor Ablation Market
7.2.4.4.1 Russia Tumor Ablation Market by Treatment
7.2.4.4.2 Russia Tumor Ablation Market by Technology
7.2.4.4.3 Russia Tumor Ablation Market by Application
7.2.4.5 Spain Tumor Ablation Market
7.2.4.5.1 Spain Tumor Ablation Market by Treatment
7.2.4.5.2 Spain Tumor Ablation Market by Technology
7.2.4.5.3 Spain Tumor Ablation Market by Application
7.2.4.6 Italy Tumor Ablation Market
7.2.4.6.1 Italy Tumor Ablation Market by Treatment
7.2.4.6.2 Italy Tumor Ablation Market by Technology
7.2.4.6.3 Italy Tumor Ablation Market by Application
7.2.4.7 Rest of Europe Tumor Ablation Market
7.2.4.7.1 Rest of Europe Tumor Ablation Market by Treatment
7.2.4.7.2 Rest of Europe Tumor Ablation Market by Technology
7.2.4.7.3 Rest of Europe Tumor Ablation Market by Application
7.3 Asia Pacific Tumor Ablation Market
7.3.1 Asia Pacific Tumor Ablation Market by Treatment
7.3.1.1 Asia Pacific Surgical Ablation Market by Country
7.3.1.2 Asia Pacific Laparoscopic Ablation Market by Country
7.3.1.3 Asia Pacific Percutaneous Ablation Market by Country
7.3.2 Asia Pacific Tumor Ablation Market by Technology
7.3.2.1 Asia Pacific Radiofrequency Ablation Market by Country
7.3.2.2 Asia Pacific Microwave Ablation Market by Country
7.3.2.3 Asia Pacific Cryoablation Market by Country
7.3.2.4 Asia Pacific Irreversible Electroporation Market by Country
7.3.2.5 Asia Pacific Other Technology Market by Country
7.3.3 Asia Pacific Tumor Ablation Market by Application
7.3.3.1 Asia Pacific Liver Cancer Market by Country
7.3.3.2 Asia Pacific Breast Cancer Market by Country
7.3.3.3 Asia Pacific Lung Cancer Market by Country
7.3.3.4 Asia Pacific Kidney Cancer Market by Country
7.3.3.5 Asia Pacific Prostate Cancer Market by Country
7.3.3.6 Asia Pacific Other Cancer Market by Country
7.3.4 Asia Pacific Tumor Ablation Market by Country
7.3.4.1 China Tumor Ablation Market
7.3.4.1.1 China Tumor Ablation Market by Treatment
7.3.4.1.2 China Tumor Ablation Market by Technology
7.3.4.1.3 China Tumor Ablation Market by Application
7.3.4.2 Japan Tumor Ablation Market
7.3.4.2.1 Japan Tumor Ablation Market by Treatment
7.3.4.2.2 Japan Tumor Ablation Market by Technology
7.3.4.2.3 Japan Tumor Ablation Market by Application
7.3.4.3 India Tumor Ablation Market
7.3.4.3.1 India Tumor Ablation Market by Treatment
7.3.4.3.2 India Tumor Ablation Market by Technology
7.3.4.3.3 India Tumor Ablation Market by Application
7.3.4.4 South Korea Tumor Ablation Market
7.3.4.4.1 South Korea Tumor Ablation Market by Treatment
7.3.4.4.2 South Korea Tumor Ablation Market by Technology
7.3.4.4.3 South Korea Tumor Ablation Market by Application
7.3.4.5 Australia Tumor Ablation Market
7.3.4.5.1 Australia Tumor Ablation Market by Treatment
7.3.4.5.2 Australia Tumor Ablation Market by Technology
7.3.4.5.3 Australia Tumor Ablation Market by Application
7.3.4.6 Singapore Tumor Ablation Market
7.3.4.6.1 Singapore Tumor Ablation Market by Treatment
7.3.4.6.2 Singapore Tumor Ablation Market by Technology
7.3.4.6.3 Singapore Tumor Ablation Market by Application
7.3.4.7 Rest of Asia Pacific Tumor Ablation Market
7.3.4.7.1 Rest of Asia Pacific Tumor Ablation Market by Treatment
7.3.4.7.2 Rest of Asia Pacific Tumor Ablation Market by Technology
7.3.4.7.3 Rest of Asia Pacific Tumor Ablation Market by Application
7.4 LAMEA Tumor Ablation Market
7.4.1 LAMEA Tumor Ablation Market by Treatment
7.4.1.1 LAMEA Surgical Ablation Market by Country
7.4.1.2 LAMEA Laparoscopic Ablation Market by Country
7.4.1.3 LAMEA Percutaneous Ablation Market by Country
7.4.2 LAMEA Tumor Ablation Market by Technology
7.4.2.1 LAMEA Radiofrequency Ablation Market by Country
7.4.2.2 LAMEA Microwave Ablation Market by Country
7.4.2.3 LAMEA Cryoablation Market by Country
7.4.2.4 LAMEA Irreversible Electroporation Market by Country
7.4.2.5 LAMEA Other Technology Market by Country
7.4.3 LAMEA Tumor Ablation Market by Application
7.4.3.1 LAMEA Liver Cancer Market by Country
7.4.3.2 LAMEA Breast Cancer Market by Country
7.4.3.3 LAMEA Lung Cancer Market by Country
7.4.3.4 LAMEA Kidney Cancer Market by Country
7.4.3.5 LAMEA Prostate Cancer Market by Country
7.4.3.6 LAMEA Other Cancer Market by Country
7.4.4 LAMEA Tumor Ablation Market by Country
7.4.4.1 Brazil Tumor Ablation Market
7.4.4.1.1 Brazil Tumor Ablation Market by Treatment
7.4.4.1.2 Brazil Tumor Ablation Market by Technology
7.4.4.1.3 Brazil Tumor Ablation Market by Application
7.4.4.2 Argentina Tumor Ablation Market
7.4.4.2.1 Argentina Tumor Ablation Market by Treatment
7.4.4.2.2 Argentina Tumor Ablation Market by Technology
7.4.4.2.3 Argentina Tumor Ablation Market by Application
7.4.4.3 UAE Tumor Ablation Market
7.4.4.3.1 UAE Tumor Ablation Market by Treatment
7.4.4.3.2 UAE Tumor Ablation Market by Technology
7.4.4.3.3 UAE Tumor Ablation Market by Application
7.4.4.4 Saudi Arabia Tumor Ablation Market
7.4.4.4.1 Saudi Arabia Tumor Ablation Market by Treatment
7.4.4.4.2 Saudi Arabia Tumor Ablation Market by Technology
7.4.4.4.3 Saudi Arabia Tumor Ablation Market by Application
7.4.4.5 South Africa Tumor Ablation Market
7.4.4.5.1 South Africa Tumor Ablation Market by Treatment
7.4.4.5.2 South Africa Tumor Ablation Market by Technology
7.4.4.5.3 South Africa Tumor Ablation Market by Application
7.4.4.6 Nigeria Tumor Ablation Market
7.4.4.6.1 Nigeria Tumor Ablation Market by Treatment
7.4.4.6.2 Nigeria Tumor Ablation Market by Technology
7.4.4.6.3 Nigeria Tumor Ablation Market by Application
7.4.4.7 Rest of LAMEA Tumor Ablation Market
7.4.4.7.1 Rest of LAMEA Tumor Ablation Market by Treatment
7.4.4.7.2 Rest of LAMEA Tumor Ablation Market by Technology
7.4.4.7.3 Rest of LAMEA Tumor Ablation Market by Application

Chapter 8. Company Profiles
8.1 Medtronic PLC
8.1.1 Company overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.1.5.2 Product Launches and Product Expansions:
8.2 Johnson and Johnson (Ethicon, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental &Regional Analysis
8.2.4 Research & Development Expenses
8.2.1 Recent strategies and developments:
8.2.1.1 Acquisition and Mergers:
8.2.1.2 Product Launches and Product Expansions:
8.3 Boston Scientific Corporation
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 Misonix, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.5 EDAP TMS S.A.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Theraclion SA
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Recent strategies and developments:
8.6.3.1 Partnerships, Collaborations, and Agreements:
8.7 AngioDynamics, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Mermaid Medical A/S
8.8.1 Company Overview
8.9 HealthTronics, Inc. (Altaris Capital Partners, LLC)
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Acquisition and Mergers:
8.9.2.2 Partnerships, Collaborations, and Agreements:
8.1 SonaCare Medical, LLC
8.10.1 Company overview
Note: Product cover images may vary from those shown
  • Medtronic PLC
  • Johnson and Johnson (Ethicon, Inc.)
  • Boston Scientific Corporation
  • Misonix, Inc.
  • EDAP TMS S.A.
  • Theraclion SA
  • AngioDynamics, Inc.
  • Mermaid Medical A/S
  • HealthTronics, Inc. (Altaris Capital Partners, LLC)
  • SonaCare Medical, LLC
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll